Filing Flows › Comparisons › ANIP vs HRMY
ANI Pharmaceuticals vs Harmony Biosciences Holdings: ANIP and HRMY compared
ANI Pharmaceuticals is the larger company: $291M of revenue in its latest quarter (Q3 2026) against $269M for Harmony Biosciences Holdings (Q3 2026). ANI Pharmaceuticals is growing faster (+28% against +12% a year earlier). Harmony Biosciences Holdings is more profitable, with an operating margin of 20.2% against 18.0%.
Where the money goes: ANIP and HRMY
ANI Pharmaceuticals (ANIP) · Q3 2026
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Harmony Biosciences Holdings (HRMY) · Q3 2026
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart follows the revenue to costs, profit and cash.
| ANI Pharmaceuticals (ANIP) | Harmony Biosciences Holdings (HRMY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $291M | $269M |
| Revenue growth, Y/Y | +28% | +12% |
| Gross margin | — | 70.0% |
| Operating margin | 18.0% | 20.2% |
| Net earnings | $35.1M | $48.2M |
| Net margin | 12.1% | 17.9% |
| Operating cash flow | $83.8M | $76.7M |
| Free cash flow | $70.3M | — |
| Market value | $1.5B | — |
| P/E | 13.7× | — |
| Analysts’ mean target | $105.78 | — |
Where the revenue comes from
ANI Pharmaceuticals
- Rare Disease and Brands total net revenues: $182M (63%)
- Generics and Other total net revenues: $108M (37%)
Questions
Which is bigger, ANI Pharmaceuticals or Harmony Biosciences Holdings?
ANI Pharmaceuticals is the larger company: $291M of revenue in its latest quarter (Q3 2026) against $269M for Harmony Biosciences Holdings (Q3 2026).
Is ANI Pharmaceuticals or Harmony Biosciences Holdings growing faster?
ANI Pharmaceuticals is growing faster (+28% against +12% a year earlier).
Which is more profitable, ANI Pharmaceuticals or Harmony Biosciences Holdings?
Harmony Biosciences Holdings is more profitable, with an operating margin of 20.2% against 18.0%.
More: ANI Pharmaceuticals earnings · how ANI Pharmaceuticals makes money · Harmony Biosciences Holdings earnings · how Harmony Biosciences Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.